Get the Stockscreener App
7.99
0.12%
-0.010
Cyclacel Pharmaceuticals Inc stock is traded at $7.99, with a volume of 42,652.
It is down -0.12% in the last 24 hours and down -25.74% over the past month.
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib. The company derives its revenue from United Kingdoms.
See More
Previous Close:
$8.00
Open:
$8
24h Volume:
42,652
Relative Volume:
0.01
Market Cap:
$17.89M
Revenue:
$74,000
Net Income/Loss:
$-13.43M
P/E Ratio:
-0.85
EPS:
-9.4
Net Cash Flow:
$-10.54M
1W Performance:
+0.50%
1M Performance:
-25.74%
6M Performance:
+46.87%
1Y Performance:
-58.39%
1-Day Range:
$7.7901
$8.1589
1-Week Range:
$6.91
$8.3486
52-Week Range:
$0.215
$39.84
Cyclacel Pharmaceuticals Inc Stock (CYCC) Company Profile
Name
Cyclacel Pharmaceuticals Inc
Sector
Industry
Phone
908-517-7330
Address
200 CONNELL DRIVE, BERKELEY HEIGHTS, NJ
Compare CYCC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CYCC
Cyclacel Pharmaceuticals Inc
|
7.99 | 11.94M | 74,000 | -13.43M | -10.54M | -9.40 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Cyclacel Pharmaceuticals Inc Stock (CYCC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
| Apr-27-20 | Resumed | ROTH Capital | Buy |
| Sep-07-18 | Initiated | Ladenburg Thalmann | Buy |
| Oct-16-15 | Initiated | H.C. Wainwright | Buy |
| Feb-04-10 | Initiated | Roth Capital | Buy |
| Oct-28-09 | Initiated | Merriman | Buy |
| Aug-12-08 | Initiated | Piper Jaffray | Buy |
| Mar-12-08 | Reiterated | Cantor Fitzgerald | Buy |
| Mar-12-08 | Reiterated | Collins Stewart | Buy |
| Mar-12-08 | Reiterated | Needham & Co | Buy |
| Nov-27-07 | Reiterated | Cantor Fitzgerald | Buy |
| Aug-10-07 | Reiterated | Cantor Fitzgerald | Buy |
| Jun-04-07 | Reiterated | Needham & Co | Buy |
| Apr-23-07 | Initiated | Lazard Capital | Buy |
| Apr-10-07 | Initiated | Cantor Fitzgerald | Buy |
View All
Cyclacel Pharmaceuticals Inc Stock (CYCC) Latest News
Cyclacel Pharmaceuticals adjusts shareholder rights, amends stock - MSN
Cyclacel Pharmaceuticals Implements Reverse Stock Split in July - MSN
Will Volume Confirm Reversal in Cyclacel Pharmaceuticals Inc.2025 Trading Volume Trends & Weekly Setup with High ROI Potential - sundaytimes.kr
Published on: 2025-08-16 06:26:36 - Newser
Long term hold vs stop loss in Cyclacel Pharmaceuticals Inc.2025 Market Sentiment & Risk Managed Trade Strategies - Newser
Cyclacel Pharmaceuticals Inc. stock prediction for this weekWeekly Gains Report & Weekly Return Optimization Alerts - Newser
Cyclacel Pharmaceuticals (NASDAQ:CYCC) Upgraded at Wall Street Zen - Defense World
Understanding Cyclacel Pharmaceuticals Inc.’s price movementJuly 2025 Patterns & Real-Time Volume Trigger Notifications - Newser
Visualizing Cyclacel Pharmaceuticals Inc. stock with heatmapsJuly 2025 Highlights & AI Driven Price Predictions - Newser
Detecting price anomalies in Cyclacel Pharmaceuticals Inc. with AIQuarterly Portfolio Review & Breakout Confirmation Trade Signals - Newser
Price momentum metrics for Cyclacel Pharmaceuticals Inc. explainedJuly 2025 Gainers & Capital Protection Trading Alerts - Newser
Published on: 2025-08-15 20:31:40 - Newser
Is Cyclacel Pharmaceuticals Inc. building a consolidation baseMarket Volume Summary & Technical Pattern Alert System - Newser
Is Cyclacel Pharmaceuticals Inc. stock forming a cup and handleTrade Risk Report & Fast Entry Momentum Trade Alerts - newsyoung.net
What makes Cyclacel Pharmaceuticals Inc. stock price move sharplyDividend Hike & Safe Capital Growth Plans - Newser
Full technical analysis of Cyclacel Pharmaceuticals Inc. stockJuly 2025 Recap & Entry Point Confirmation Signals - Newser
Using Python tools to backtest Cyclacel Pharmaceuticals Inc. strategiesWeekly Trade Analysis & Reliable Trade Execution Plans - Newser
Using data models to predict Cyclacel Pharmaceuticals Inc. stock movementWeekly Earnings Recap & AI Based Buy/Sell Signal Reports - Newser
Historical volatility pattern of Cyclacel Pharmaceuticals Inc. visualizedEarnings Performance Report & Weekly Momentum Stock Picks - Newser
Cyclacel Pharmaceuticals, Inc. SEC 10-Q Report - TradingView
Cyclacel Pharmaceuticals Reports Q2 2025 Financial Results - TipRanks
Is Cyclacel Pharmaceuticals Inc. still worth holding after the dipJuly 2025 PostEarnings & Risk Controlled Stock Pick Alerts - Newser
Cyclacel reports Q2 financials, declares $0.15/share dividend. - AInvest
Cyclacel Pharmaceuticals, Inc. Reports Second Quarter 2025 Financial Results and Business Developments - Quiver Quantitative
Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update - The Manila Times
Cyclacel Pharmaceuticals Slashes Losses to $1.3M, Plans Strategic Malaysian Expansion - Stock Titan
Cyclacel Pharmaceuticals files audited Q1 financials to support S-3 eligibility - Investing.com Nigeria
Cyclacel Pharmaceuticals Announces $1 Million Private Placement Offering of Convertible Preferred Stock - The Globe and Mail
Is Cyclacel Pharmaceuticals Inc. forming a reversal patternFree Fundamental Winners With Safe Entry Plan - Newser
Published on: 2025-08-11 05:10:53 - Newser
Cyclacel Pharmaceuticals Announces That Kenneth M. Ferguson, Ph.D. Was Elected to Its Board of Directors - The Globe and Mail
Cyclacel Pharmaceuticals Inc (CYCC) Stock: Uncovering a 52-Week Range and Trading Volume - investchronicle.com
Cyclacel Stock Surges 50% After Amending Exchange Agreement with FITTERS - MSN
Cyclacel (CYCC) Stock Sees Strong Pre-Market Performance After New Study Results - 富途牛牛
Cyclacel Pharmaceuticals Inc. (CYCC) Soars 34.86% on Encouraging Preclinical Results - AInvest
CYCLACEL PHARMACEUTICALS HIGHLIGHTS PRECLINICAL DATA SHOWING THAT CANCER OF THE BILIARY TRACT IS SENSITIVE TO PLOGOSERTIB - The Manila Times
Cyclacel Pharmaceuticals Stock Up 34.6% In Massive After-Hours Rally - Benzinga
Major Shareholder Cashes Out on Cyclacel Pharmaceuticals Stock! - TipRanks
Cyclacel Pharmaceuticals Highlights Promising Preclinical Study on Plogosertib for Treating Biliary Tract Cancer - Quiver Quantitative
Breakthrough: Novel Drug Plogosertib Effectively Targets Aggressive Biliary Cancer, Study Reveals Key Biomarker - Stock Titan
WeightWatchers Reschedules Second Quarter 2025 Earnings Release and Conference Call to Finalize Fresh Start Accounting Adoption in Connection with Emergence - The Globe and Mail
Recovery Signals Appearing in Cyclacel Pharmaceuticals Inc. ChartsMarket Entry and Exit Point Tips From Traders - beatles.ru
What are the technical indicators suggesting about Cyclacel Pharmaceuticals Inc.Tap into rapid wealth building techniques - Jammu Links News
What are analysts’ price targets for Cyclacel Pharmaceuticals Inc. in the next 12 monthsInvest in stocks with strong fundamentals - Jammu Links News
Is Cyclacel Pharmaceuticals Inc. stock overvalued or undervaluedAchieve breakthrough gains with expert advice - Jammu Links News
What are Cyclacel Pharmaceuticals Inc. company’s key revenue driversDynamic investment opportunities - Jammu Links News
How volatile is Cyclacel Pharmaceuticals Inc. stock compared to the marketAchieve breakthrough gains with smart trades - Jammu Links News
How does Cyclacel Pharmaceuticals Inc. compare to its industry peersUnlock powerful trading tools for investors - Jammu Links News
What is the dividend policy of Cyclacel Pharmaceuticals Inc. stockInvest smarter with actionable stock recommendations - Jammu Links News
What institutional investors are buying Cyclacel Pharmaceuticals Inc. stockHigh-yield investments - Jammu Links News
What drives Cyclacel Pharmaceuticals Inc. stock priceCapitalize on stocks with high profit margins - Jammu Links News
Cyclacel Pharmaceuticals Inc Stock (CYCC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cyclacel Pharmaceuticals Inc Stock (CYCC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lazar David E. | Interim CEO |
Feb 26 '25 |
Sale |
0.03 |
194,628,820 |
5,507,996 |
0 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):